Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
No open-market purchases or sales by Cadrenal Therapeutics, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Cadrenal Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 10 | 16 | +6 |
| Shares | 14.9K | 69.4K | +54.5K (+366.4%) |
| Value | $215.5K | $1.22M | +$1.01M (+467.5%) |
New holders (8)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 45,633 | $804.5K | 0.00% |
| Jones Financial Companies LLLP | 172 | $3.17K | 0.00% |
| JPMorgan Chase & Co | 100 | $1.76K | 0.00% |
| Wells Fargo & Company | 100 | $1.76K | 0.00% |
| UMA Financial Services, Inc. | 52 | $917 | 0.00% |
| IFP Advisors, Inc | 30 | $529 | 0.00% |
| Frazier Financial Advisors, LLC | 10 | $177 | 0.00% |
| Caldwell Sutter Capital, Inc. | 5 | $88 | 0.00% |
Sold out (2)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Tower Research Capital LLC (TRC) | 368 | $5.33K |
| R Squared Ltd | 40 | $580 |